Viking Therapeutics, Inc.
NASDAQ:VKTX
64.45 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.292 | 0.291 | 0.296 | 0.277 | 0.26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.292 | -0.291 | -0.296 | -0.277 | -0.26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 63.806 | 54.234 | 44.981 | 31.931 | 23.559 | 19.04 | 13.741 | 9 | 6.967 | 22.223 | 0.012 | 0 |
| General & Administrative Expenses
| 37.021 | 16.121 | 10.701 | 10.731 | 9.128 | 7.121 | 5.329 | 4.847 | 5.03 | 1.245 | 0.089 | 0 |
| Selling & Marketing Expenses
| -0.292 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 36.729 | 16.121 | 10.701 | 10.731 | 9.128 | 7.121 | 5.329 | 4.847 | 5.03 | 1.245 | 0.089 | 0 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 1.398 | 0.345 | 1.064 | -10.425 | 2.212 | -0.021 | 0 |
| Operating Expenses
| 100.535 | 70.355 | 55.682 | 42.662 | 32.687 | 26.161 | 19.07 | 13.847 | 11.996 | 23.468 | 0.101 | 0 |
| Operating Income
| -100.827 | -70.355 | -55.682 | -42.662 | -32.687 | -26.161 | -19.07 | -13.847 | -11.996 | -23.468 | -0.101 | -0 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 14.932 | 1.488 | 0.692 | 3.167 | 6.908 | 1.386 | 0.345 | 1.064 | -10.425 | 2.212 | -0.021 | -0 |
| Income Before Tax
| -85.895 | -68.867 | -54.99 | -39.495 | -25.779 | -22.063 | -20.578 | -14.732 | -23.404 | -21.884 | -0.146 | -0 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -1.488 | -0.988 | -3.444 | 6.992 | -2.712 | 1.852 | 1.949 | 0.982 | 0.629 | 0.025 | -0 |
| Net Income
| -85.895 | -67.379 | -54.002 | -36.051 | -25.779 | -22.063 | -20.578 | -14.732 | -23.404 | -21.884 | -0.146 | -0 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.91 | -0.88 | -0.7 | -0.5 | -0.36 | -0.38 | -0.79 | -0.9 | -3.68 | -5.08 | -0.034 | -0.3 |
| EPS Diluted
| -0.91 | -0.88 | -0.7 | -0.5 | -0.36 | -0.38 | -0.79 | -0.9 | -3.68 | -5.08 | -0.034 | -0.3 |
| EBITDA
| -100.535 | -70.313 | -55.689 | -42.702 | -25.523 | -21.647 | -19.295 | -12.922 | -22.422 | -21.256 | -0.122 | -0 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |